Alnylam Pharma (ALNY) Tops Q3 EPS by 21c
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $229.30 --0%
Financial Fact:
Net revenues from research collaborators: 8.71M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Net revenues from research collaborators: 8.71M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q3 EPS of ($1.06), $0.21 better than the analyst estimate of ($1.27). Revenue for the quarter came in at $17.1 million versus the consensus estimate of $24.65 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BMO Capital Starts Alnylam Pharmaceuticals (ALNY) at Outperform
- Analog Devices (ADI) Tops Q3 EPS by 11c, Beats on Revenue; Offers Q4 Guidance
- Flowers Foods (FLO) Misses Q2 EPS by 3c; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
